Becker's Healthcare January 14, 2025
Alexandra Murphy

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13.

The company is preparing to release key late-stage trial data on the drug by mid-2025. The weight loss pill aims to compete with popular injectable treatments like Eli Lilly’s own Zepbound and Novo...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says
Google DeepMind CEO: AI-Designed Drugs Coming to Clinical Trials in 2025
Moderna gets $590M from US government for bird flu vaccine
Why costly gene therapy is top of mind for benefits administrators
CEPI provides $6.2m to push first mRNA-based Rift Valley fever vaccine into trial

Share This Article